Platelet function monitoring in patients with coronary artery disease.
Studies focused on patient responsiveness to antiplatelet therapies, particularly aspirin and clopidogrel, have increased in recent years. However, the relations of in vivo platelet function and adverse clinical events to results of ex vivo platelet function tests remain largely unknown. This article describes current methods of measuring platelet function in various clinical and research situations and their advantages and disadvantages, reviews evidence for antiplatelet response variability and resistance, discusses the potential pitfalls of monitoring platelet function, and demonstrates emerging data supporting the positive clinical and treatment implications of platelet function testing.
Gurbel
Paul A
PA
Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland, USA.
Becker
Richard C
RC
Mann
Kenneth G
KG
Steinhubl
Steven R
SR
Michelson
Alan D
AD
D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D000077144:Clopidogrel; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy; D003327:Coronary Disease / Q000097:blood* / Q000188:drug therapy; D004351:Drug Resistance; D006801:Humans; D008991:Monitoring, Physiologic; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D010979:Platelet Function Tests; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D012307:Risk Factors; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin